Heterocyclic compound

Abstract

Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

1 - 20 . (canceled) 
     
     
         21 . A method for the prophylaxis or treatment of cancer in a mammal, which comprises administering an effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
       
       wherein
 one of X and Y is a sulfur atom, and the other is CH, 
 R 1  is a C 1-6  alkyl group optionally substituted by halogen atom(s), 
 R 2  is a substituent, 
 or a salt thereof, to the mammal. 
 
     
     
         22 . The method of  claim 21 , wherein X is a sulfur atom; and
 Y is CH.   
     
     
         23 . The method of  claim 21 , wherein R 2  is a hydrocarbon group optionally having substituent(s),
 a heterocyclic group optionally having substituent(s), or a non-aromatic heterocyclyl-carbonyl group optionally having substituent(s).   
     
     
         24 . The method of  claim 21 , wherein R 2  is
 (1) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (a) a non-aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (i) a halogen atom, 
 (ii) a hydroxy group, 
 (iii) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (aa) a halogen atom, 
 (bb) a hydroxy group, 
 (cc) a C 1-6  alkoxy group, and 
 (dd) a C 6-14  aryl group optionally substituted by 1 to 3 C 1-6  alkyl groups, 
 
 (iv) a C 1-6  alkoxy group, 
 (v) a C 6-14  aryl group optionally substituted by 1 to 3 halogen atoms, 
 (vi) a C 6-14  aryloxy group, 
 (vii) a C 1-6  alkoxy-carbonyl group, 
 (viii) a C 1-6  alkyl-carbonyl group, 
 (ix) a cyano group, 
 (x) a C 6-14  arylsulfonyl group, 
 (xi) a carboxy group, 
 (xii) an amino group optionally mono- or di-substituted by a C 1-6  alkyl group, 
 (xiii) a non-aromatic heterocyclic group optionally substituted by an oxo group, and 
 (xiv) an oxo group, 
 
 (b) a C 1-6  alkoxy group, 
 (c) an amino group optionally mono- or di-substituted by substituent(s) selected from
 (i) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (aa) a C 6-14  aryl group optionally substituted by 1 to 3 C 1-6  alkoxy groups, 
 (bb) a C 1-6  alkoxy-carbonyl group, 
 (cc) an aromatic heterocyclic group, 
 (dd) a C 3-8  cycloalkyl group optionally substituted by an aromatic heterocyclic group, and 
 (ee) a hydroxy group, 
 
 (ii) a non-aromatic heterocyclic group optionally substituted by 1 to 3 C 7-13  aralkyl groups, 
 (iii) a C 6-14  aryl group optionally substituted by 1 to 3 C 1-6  alkoxy groups, and 
 (iv) a C 3-8  cycloalkyl group, 
 
 (d) a 5- or 6-membered aromatic heterocyclic group, 
 (e) a C 6-14  aryl group, and 
 (f) a C 3-8  cycloalkyl group optionally substituted by an amino group; 
   (2) a C 6-14  aryl group optionally substituted by 1 to 3 halogen atoms;   (3) a non-aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (a) a halogen atom, 
 (b) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from
 (i) a hydroxy group, 
 (ii) a C 1-6  alkoxy-carbonyl group, and 
 (iii) a carbamoyl group, 
 
 (c) a C 6-14  aryloxy group, 
 (d) a C 1-6  alkoxy-carbonyl group, 
 (e) a C 1-6  alkyl-carbonyl group, 
 (f) a C 6-14  aryl group optionally substituted by a C 1-6  alkylsulfonyl group, 
 (g) a C 7-13  aralkyl group optionally substituted by 1 to 3 halogen atoms, 
 (h) a hydroxy group, 
 (i) a carbamoyl group, and 
 (j) a non-aromatic heterocyclic group; 
   (4) a C 2-6  alkenyl group optionally substituted by 1 to 3 C 6-14  aryl groups;   (5) a 5- or 6-membered aromatic heterocyclic group;   (6) a non-aromatic heterocyclyl-carbonyl group; or   (7) a C 3-8  cycloalkyl group optionally substituted by an amino group.   
     
     
         25 . The method of  claim 21 , wherein R 2  is
 (1) a 4- to 6-membered non-aromatic heterocyclyl-C 1-6  alkyl group optionally substituted by 1 to 3 halogen atoms;   (2) a C 6-14  aryl group optionally substituted by 1 to 3 halogen atoms; or   (3) a non-aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (a) a halogen atom, and 
 (b) a C 1-6  alkyl group. 
   
     
     
         26 . The method of  claim 25 , wherein R 2  is a bridged non-aromatic heterocyclic group. 
     
     
         27 . The method of  claim 26 , wherein R 2  is selected from a azabicyclo[3.1.0]hexanyl, a azabicyclo[2.2.1]heptanyl, a azabicyclo[2.2.1]hexyanyl, and a azabicyclo[2.2.2]octanyl. 
     
     
         28 . The method of  claim 27 , wherein R 2  is a azabicyclo[2.2.2]octanyl. 
     
     
         29 . The method of  claim 28 , wherein X is a sulfur atom;
 Y is CH; and   R 1  is a C 1-6  alkyl group.   
     
     
         30 . The method of  claim 21 , wherein R 1  is a C 1-6  alkyl group.